YU87892A - Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu - Google Patents

Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu

Info

Publication number
YU87892A
YU87892A YU87892A YU87892A YU87892A YU 87892 A YU87892 A YU 87892A YU 87892 A YU87892 A YU 87892A YU 87892 A YU87892 A YU 87892A YU 87892 A YU87892 A YU 87892A
Authority
YU
Yugoslavia
Prior art keywords
growth hormone
carrier
injectible
procedures
obtaining
Prior art date
Application number
YU87892A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
N.D. Brooks
G.F. Needham
Original Assignee
Eli Lilly And Company Lilly Corporate Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company Lilly Corporate Center filed Critical Eli Lilly And Company Lilly Corporate Center
Publication of YU87892A publication Critical patent/YU87892A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
YU87892A 1991-10-01 1992-02-29 Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu YU87892A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76955591A 1991-10-01 1991-10-01

Publications (1)

Publication Number Publication Date
YU87892A true YU87892A (sh) 1995-12-04

Family

ID=25085803

Family Applications (1)

Application Number Title Priority Date Filing Date
YU87892A YU87892A (sh) 1991-10-01 1992-02-29 Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu

Country Status (4)

Country Link
US (1) US5352662A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW269638B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU87892A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA927329B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW282403B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1993-08-26 1996-08-01 Takeda Pharm Industry Co Ltd
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
EP0873134B1 (en) 1996-01-11 2003-04-23 PHARMACIA & UPJOHN COMPANY Aqueous prolonged release formulation comprising bovine growth hormone-releasing factor
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US7919109B2 (en) * 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
EP1064934A1 (en) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
US6960346B2 (en) 2002-05-09 2005-11-01 University Of Tennessee Research Foundation Vehicles for delivery of biologically active substances
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CA2779723C (en) * 2002-12-13 2014-03-25 Durect Corporation Oral drug delivery system
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US8753665B2 (en) 2004-09-17 2014-06-17 Durect Corporation Controlled delivery system
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
CN101511170B (zh) * 2005-12-22 2014-03-26 奥克伍德药业有限公司 可升华持续释放传递系统和其制造方法
CN101453982B (zh) 2006-05-30 2011-05-04 精达制药公司 两件式内部通道渗透递送系统流动调节器
JP5048773B2 (ja) 2006-08-09 2012-10-17 インターシア セラピューティクス，インコーポレイティド 浸透圧式デリバリーシステム及びピストンアセンブリー
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
PL2157967T3 (pl) 2007-04-23 2013-06-28 Intarcia Therapeutics Inc Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
EP2067471B1 (en) 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2010056657A2 (en) 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
KR20150006083A (ko) 2009-09-28 2015-01-15 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
HK1220579A1 (zh) 2013-03-15 2017-05-12 Durect Corporation 用於降低溶解可变性的具有流变改性剂的组合物
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
CL2016000217A1 (es) * 2016-01-27 2016-07-01 Farmacologia En Aquacultura Veterinaria Fav S A Nueva composición veterinaria inyectable para la sincronización del desove en peces
JP7077237B2 (ja) 2016-05-16 2022-05-30 インターシア セラピューティクス，インコーポレイティド グルカゴン受容体選択的ポリペプチド及びその使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN109475505A (zh) 2016-07-06 2019-03-15 度瑞公司 具有药物组成物、屏障层及药物层的口服剂型
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58172311A (ja) * 1982-04-02 1983-10-11 Kodama Kk 持続性製剤及びその製法
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
JPS61114676A (ja) * 1984-11-09 1986-06-02 Nec Corp ブロツク符号化装置
DE3579911D1 (de) * 1984-12-24 1990-10-31 Sumitomo Pharma Stabiles grf-praeparat.
IL79681A (en) * 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
US4775659A (en) * 1985-08-19 1988-10-04 Eli Lilly And Company Injectable semi-solid formulations
US4977140A (en) * 1985-08-23 1990-12-11 Eli Lilly And Company Injectable sustained release formulation
ZA866218B (en) * 1985-08-23 1988-03-30 Lilly Co Eli Injectable sustained release formulation
US4784845A (en) * 1985-09-16 1988-11-15 American Cyanamid Company Emulsion compostions for the parenteral administration of sparingly water soluble ionizable hydrophobic drugs
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
SE457693B (sv) * 1986-07-01 1989-01-23 Drilletten Ab Komposition med reglerad frigoering vari ett biologiskt material aer loest eller dispergerat i en l2-fas
ATE74009T1 (de) * 1986-08-11 1992-04-15 American Cyanamid Co Zusammensetzungen zur parenteralen verabreichung und deren verwendung.
US4837381A (en) * 1986-08-11 1989-06-06 American Cyanamid Company Compositions for parenteral administration and their use
US4857506A (en) * 1987-01-12 1989-08-15 American Cyanamid Company Sustained release growth hormone compositions for parenteral administration and their use
US4857505A (en) * 1987-03-09 1989-08-15 American Cyanamid Company Sustained release compositions for parenteral administration and their use
GB8725427D0 (en) * 1987-10-30 1987-12-02 Lilly Industries Ltd Somatotropin formulations
AU645003B2 (en) * 1988-11-08 1994-01-06 Takeda Chemical Industries Ltd. Sustained release preparations

Also Published As

Publication number Publication date
TW269638B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1996-02-01
ZA927329B (en) 1994-03-24
US5352662A (en) 1994-10-04

Similar Documents

Publication Publication Date Title
YU87892A (sh) Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu
KR100561255B1 (ko) 호르몬 방출용 트랜스더멀 치료 시스템
MX9204770A (es) Composiciones para lapices cosmeticos y procedimiento para su preparacion.
HRP20000366B1 (en) Long acting injectable formulations containing hydrogenated castor oil
ES2090981T3 (es) Efecto de la distribucion del tamaño de particulas de eteres de celulosa sobre la palatabilidad de composiciones.
ES2180536T3 (es) Sistema de administracion de un farmaco basado en el parametro de solubilidad y metodo para alterar la concentracion de saturacion del farmaco.
DE69815659D1 (de) Zusammensetzung zur kontrollierten freisetzung
SE8405922L (sv) Antibiotikahaltigt medel och anvendningen derav sasom kirurgiskt plastmaterial
ES2078929T3 (es) Emplasto que contiene estrogenos.
DE69311278D1 (de) Stabile pharmazeutische Zubereitung mit Fumagillolderivaten
DE69508985D1 (de) Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe
DE69510348D1 (de) Zweistufiger flüssigkeitsabgabe köderhalter
DE69836656D1 (de) Bioabsorbierbare Markierungen mit röntgendichten Bestandteilen
BG93923A (bg) Метод за получаване на състав за контролирано освобождаване на активното вещество
MX9203310A (es) Implante de colageno que contiene ingrediente o ingredientes activos para injertacion en huesos o tejidos blandos y procedimiento para su fabricacion.
SE9201128L (sv) Artificiellt fyllnings- och protesmaterial
ATE69725T1 (de) Pharmazeutische zubereitungen von acrivastine.
NO894465L (no) Preparat med oekt penetrasjon gjennom huden.
MX172804B (es) Composicion de cebo para insectos en forma de tableta y procedimiento para su preparacion
ES2194051T3 (es) Modificador y composicion modificadora para sustancias que contienen proteinas.
PT769951E (pt) Composicao de oxitetraciclina de longa accao
MX9400148A (es) Composicion de somatotropina implantable de liberacion prolongada.
ES2150902T3 (es) Procedimientos para potenciar la cicatrizacion de heridas y la reparacion de tejidos.
GB1250573A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX9806182A (es) Medicamento antiglucocorticoide.